These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21121812)

  • 1. Pharmacogenetics of controlled ovarian hyperstimulation: time to corroborate the clinical utility of FSH receptor genetic markers.
    Morón FJ; Ruiz A
    Pharmacogenomics; 2010 Nov; 11(11):1613-8. PubMed ID: 21121812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation.
    Behre HM; Greb RR; Mempel A; Sonntag B; Kiesel L; Kaltwasser P; Seliger E; Röpke F; Gromoll J; Nieschlag E; Simoni M
    Pharmacogenet Genomics; 2005 Jul; 15(7):451-6. PubMed ID: 15970792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of follicle-stimulating hormone receptor N680S polymorphism on the efficacy of follicle-stimulating hormone stimulation on donor ovarian response.
    Lledo B; Guerrero J; Turienzo A; Ortiz JA; Morales R; Ten J; Llacer J; Bernabeu R
    Pharmacogenet Genomics; 2013 May; 23(5):262-8. PubMed ID: 23470615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacogenetic-driven approach for controlled ovarian hyperstimulation by FSH treatment.
    Colognato R; Aiello R; Dulcetti F; Ruggeri AM; De Toffol S; Marcato L; Irollo AM; Criscuolo C; Gangale MF; Maggi F; Simoni G
    Minerva Ginecol; 2014 Dec; 66(6):543-9. PubMed ID: 25373014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of controlled ovarian hyperstimulation.
    de Castro F; Morón FJ; Montoro L; Real LM; Ruiz A
    Pharmacogenomics; 2005 Sep; 6(6):629-37. PubMed ID: 16143002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics in ovarian stimulation--current concepts.
    Loutradis D; Vlismas A; Drakakis P; Antsaklis A
    Ann N Y Acad Sci; 2008 Apr; 1127():10-9. PubMed ID: 18443324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating influence of the genotypes in the follicle-stimulating hormone receptor (FSHR) Ser680Asn (rs6166) polymorphism on poor and hyper-responders to ovarian stimulation: a meta-analysis.
    Pabalan N; Trevisan CM; Peluso C; Jarjanazi H; Christofolini DM; Barbosa CP; Bianco B
    J Ovarian Res; 2014 Dec; 7():285. PubMed ID: 25526787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies.
    Tang H; Yan Y; Wang T; Zhang T; Shi W; Fan R; Yao Y; Zhai S
    J Assist Reprod Genet; 2015 Dec; 32(12):1801-10. PubMed ID: 26481502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today?
    Altmäe S; Hovatta O; Stavreus-Evers A; Salumets A
    Hum Reprod Update; 2011; 17(6):813-28. PubMed ID: 21862569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization.
    La Marca A; Sighinolfi G; Argento C; Grisendi V; Casarini L; Volpe A; Simoni M
    Fertil Steril; 2013 Mar; 99(4):970-8.e1. PubMed ID: 23380184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation.
    Nenonen HA; Lindgren IA; Prahl AS; Trzybulska D; Kharraziha I; Hultén M; Giwercman YL; Henic E
    Pharmacogenet Genomics; 2019 Jul; 29(5):114-120. PubMed ID: 30829738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of ovarian response.
    Lledo B; Ortiz JA; Llacer J; Bernabeu R
    Pharmacogenomics; 2014 Apr; 15(6):885-93. PubMed ID: 24897293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic complexity of FSH receptor function.
    Gromoll J; Simoni M
    Trends Endocrinol Metab; 2005 Oct; 16(8):368-73. PubMed ID: 16126408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of follicle-stimulating hormone action.
    Laan M; Grigorova M; Huhtaniemi IT
    Curr Opin Endocrinol Diabetes Obes; 2012 Jun; 19(3):220-7. PubMed ID: 22499219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms in endocrinology: Genetics of FSH action: a 2014-and-beyond view.
    Simoni M; Casarini L
    Eur J Endocrinol; 2014 Mar; 170(3):R91-107. PubMed ID: 24288354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of urinary versus recombinant follicle-stimulating hormone on platelet function and other hemostatic variables in controlled ovarian hyperstimulation.
    Bar J; Orvieto R; Lahav J; Hod M; Kaplan B; Fisch B
    Fertil Steril; 2004 Dec; 82(6):1564-9. PubMed ID: 15589861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic profile of SNP(s) and ovulation induction.
    Loutradis D; Theofanakis C; Anagnostou E; Mavrogianni D; Partsinevelos GA
    Curr Pharm Biotechnol; 2012 Mar; 13(3):417-25. PubMed ID: 21657995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor ovarian response to gonadotropin stimulation is associated with low expression of follicle-stimulating hormone receptor in granulosa cells.
    Cai J; Lou HY; Dong MY; Lu XE; Zhu YM; Gao HJ; Huang HF
    Fertil Steril; 2007 Jun; 87(6):1350-6. PubMed ID: 17296182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human controlled ovarian hyperstimulation outcome is a polygenic trait.
    de Castro F; Morón FJ; Montoro L; Galán JJ; Hernández DP; Padilla ES; Ramírez-Lorca R; Real LM; Ruiz A
    Pharmacogenetics; 2004 May; 14(5):285-93. PubMed ID: 15115914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
    Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
    J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.